CAREERS

• Application Dates:

  23 Sep, 2019 12AM – 18 Nov, 2019 11PM

The Challenge

Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch products or solutions to drive growth for our Nyal brand in the Australian market, the #1 Cough Liquid & Nasal Spray Brand*. We are interested in novel and unique delivery systems for natural ingredients, such as menthol, to clear the nose and head for immediate relief. Appealing formats could include inhaler sticks, topical rub sticks, sprays, patches or vapourisers which are suitable for use both at home and on-the-go. The product should also be differentiated from current competitors.

Ideal Solution

How can iNova better meet the needs of consumers in delivering better products? The following describes our ideal solution, but not all criteria needs to be met to apply.

• your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
• your products/formulations are a strong fit for the Nyal brand portfolio
• your products are available to sell in Australia
• you already produce products/prototypes containing evidence-based ingredients or clinically proven formula/mode of action on your behalf or on behalf of third parties
• you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
• you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
• your organisation is nimble and able to support fast development and manufacturing

What is the Opportunity?

Leading Innovators will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on the strong, well-known Nyal branding – familiar to the Australian consumer. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia. Should the idea be also valid for our other regions, there will also be the opportunity to extend the products to Asia and South Africa where we have a presence (possibly under a different brand).

What is the Process?

Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. The chosen finalists will then pitch their solution and partnership proposal to the iNova executive team. The leading solution(s) will then be launched in Australia, under the mutually agreed partnership model.

APPLICATIONS NOW CLOSED

If you have any questions, please do not hesitate to contact ipitch@inovapharma.com

* Aztec Grocery Scan Sales (17.02.19)

Products featured in this website or on the photos/images may or may not be approved or available in the country that you are accessing this website from. iNova’s products will have different labelling and be subject to different regulatory requirements in different countries. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product that is not approved under the laws and regulations of the country that you are accessing this website from.

• Application Dates:

  23 Sep, 2019 12AM – 18 Nov, 2019 11PM

The Challenge

Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch products or solutions to drive growth for our Difflam brand in Australasia or Andolex brand in South Africa. Difflam is the #1 sore throat brand in pharmacy in Australia*. Andolex is South Africa’s leading brand for sore throat and mouth**. We are looking for innovative products or ingredients which treat sore throats across all life stages from young children to the elderly.

Ideal Solution

How can iNova better meet the needs of consumers in delivering sore throat solutions across different life stages? The following describes our ideal solution, but not all criteria needs to be met to apply.

• your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
• your products/formulations are a strong fit for the Difflam and Andolex brand portfolio
• your products are available to sell in Australia/New Zealand, Asia and/or South Africa
• you already produce products/prototypes containing scientifically proven ingredients or clinically proven formula/mode of action on your behalf or on behalf of third parties
• you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
• you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
• your organisation is nimble and able to support fast development and manufacturing

What is the Opportunity?

Leading Innovators will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.

What is the Process?

Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. The chosen finalists will then pitch their solution and partnership proposal to the iNova executive team. The leading solution(s) will then be launched into one or more of our regions, under the mutually agreed partnership model.

APPLICATIONS NOW CLOSED

If you have any questions, please do not hesitate to contact ipitch@inovapharma.com

* Aztec Pharmacy Scan Sales 09.06.19

** IMS Total Private Market Value MAT. December 2018.

Products featured in this website or on the photos/images may or may not be approved or available in the country that you are accessing this website from. iNova’s products will have different labelling and be subject to different regulatory requirements in different countries. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product that is not approved under the laws and regulations of the country that you are accessing this website from.

• Application Dates:

  23 Sep, 2019 12AM – 18 Nov, 2019 11PM

The Challenge

We are looking for wild card applicants with novel products, technology, services or ideas to help drive growth for our key brands in our three regions – Australia & New Zealand, South Africa and Asia.
Our key focus categories for this wild card challenge include:

• skincare – specifically, sun care, baby skin care, and skin conditions like: extreme sensitive skin, extreme dry skin, psoriasis, eczema, rosacea, keratosis pilaris, acne
• throat, cough, cold, flu, sinus, allergy – including all stages of the cycle from: prevention > early signs > peak sickness > recovery > prevention > immune boosting
• feminine health – specifically covering stages of a female life from: puberty > pre-conception > pregnancy > post partum > pre-menopause > post-menopause

Our key brands in these focus categories include: Difflam, DURO-TUSS, Demazin, BLIS PROBIOTICS, Nyal, DermaVeen, Andolex, Rupanase, Pholtex, FLUGON, Allerguard, PregOmega, Sinopol, Dequadin, Valda.

Ideal Solution

The following describes our ideal solution, but not all criteria needs to be met to apply.

• your idea, technology, or solution addresses a health need and consumer benefit in one of these focus categories
• your solution is a strong fit for our key brands and complement to its range
• your solution can be implemented in at least one of our three regions – ANZ, RSA and Asia
• you are willing and authorised to negotiate an agreement to potentially partner with iNova Pharmaceuticals to implement the solution
• you/your organisation is nimble and able to support fast implementation of your solution

What is the Opportunity?

The leading Innovator will choose how they want to work with iNova Pharmaceuticals to implement the solution.

What is the Process?

Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. The chosen finalists will then pitch their solution and partnership proposal to the iNova executive team. The leading solution(s) will then be launched into one or more of our regions, under the mutually agreed partnership model.

APPLICATIONS NOW CLOSED

If you have any questions, please do not hesitate to contact ipitch@inovapharma.com

Products featured in this website or on the photos/images may or may not be approved or available in the country that you are accessing this website from. iNova’s products will have different labelling and be subject to different regulatory requirements in different countries. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product that is not approved under the laws and regulations of the country that you are accessing this website from.

• Application Dates:

  23 Sep, 2019 12AM – 18 Nov, 2019 11PM

The Challenge

Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch products or solutions to drive growth for our Dermatix brand, Australia’s #1 scar reduction gel*.

Ideal Solution

How can iNova better meet the needs of consumers in delivering wounds and scar solutions? The following describes our ideal solution, but not all criteria needs to be met to apply.

• your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
• your products/formulations are a strong fit for the Dermatix brand portfolio
• your products are available to sell in Australia and/or New Zealand
• your product can be sold over the counter, without a Doctor’s script
• you already produce products/prototypes containing evidence-based ingredients or clinically proven formula/mode of action on your behalf or on behalf of third parties
• you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
• you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
• your organisation is nimble and able to support fast development and manufacturing

What is the Opportunity?

Leading Innovators will partner with iNova Pharmaceuticals to take their product to the next level, leveraging the Dermatix branding – familiar to Australian and New Zealand consumers. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across ANZ. Should the idea be valid for other iNova regions, there will also be the opportunity to extend the products to Asia and South Africa where iNova have a presence (possibly under a different brand).

What is the Process?

Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. The chosen finalists will then pitch their solution and partnership proposal to the iNova executive team. The leading solutions will then be launched in Australia and/or New Zealand, under the mutually agreed partnership model.

APPLICATIONS NOW CLOSED

If you have any questions, please do not hesitate to email ipitch@inovapharma.com

* Aztec Pharmacy Scan Data (Value), Scar Treatment Gels. MAT 9/6/19

Products featured in this website or on the photos/images may or may not be approved or available in the country that you are accessing this website from. iNova’s products will have different labelling and be subject to different regulatory requirements in different countries. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product that is not approved under the laws and regulations of the country that you are accessing this website from.